Synthekine

Synthekine company information, Employees & Contact Information

Updated June 2026

Quick answer

Synthekine is a Biotechnology Research company and founded in 2018. It has approximately 77 employees on record. Contact data was last refreshed in June 2026. Find Synthekine's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Company Details

Employees
77
Founded
2018
Address
1505 Obrien Dr, Menlo Park,california 94025,united States
Phone
(650) 271-9888
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Menlo Park, California
Looking for a particular Synthekine employee's phone or email?

Synthekine Questions

News

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks - Endpoints News

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks Endpoints News

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting - BioSpace

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting BioSpace

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 - Business Wire

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024 Business Wire

Synthekine’s STK-012 demonstrates potential in solid tumour trial - Clinical Trials Arena

Synthekine’s STK-012 demonstrates potential in solid tumour trial Clinical Trials Arena

Study of SYNCAR-001 and STK-009 Begins in CD19+ Hematologic Malignancies - Targeted Oncology

Study of SYNCAR-001 and STK-009 Begins in CD19+ Hematologic Malignancies Targeted Oncology

Sanofi partners with Synthekine to develop IL-10 therapeutics - Pharmaceutical Technology

Sanofi partners with Synthekine to develop IL-10 therapeutics Pharmaceutical Technology

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - BioSpace

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting BioSpace

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class - Fierce Biotech

AACR: Synthekine hopes new IL-2 will be the high-alpha in a beta class Fierce Biotech

Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies - Genetic Engineering and Biotechnology News

Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies Genetic Engineering and Biotechnology News

Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine - MedCity News

Sanofi Tries Again With Cytokines, Inking R&D Alliance With Startup Synthekine MedCity News

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy - Frontiers

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy Frontiers

Naiyer Rizvi named CMO of Synthekine - The Cancer Letter

Naiyer Rizvi named CMO of Synthekine The Cancer Letter

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion - Business Wire

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion Business Wire

Synthekine dosed first patient in Phase 1 trial of its IL-2 treatment STK-012 in solid tumors - PPF Group

Synthekine dosed first patient in Phase 1 trial of its IL-2 treatment STK-012 in solid tumors PPF Group

Synthekine scores major $108M B round to secure set of trials in 12 months - Fierce Biotech

Synthekine scores major $108M B round to secure set of trials in 12 months Fierce Biotech

One of a 'Kine': Synthekine Engineers Cytokine Therapeutics to Treat Cancer and Inflammatory Disease - Genetic Engineering and Biotechnology News

One of a 'Kine': Synthekine Engineers Cytokine Therapeutics to Treat Cancer and Inflammatory Disease Genetic Engineering and Biotechnology News

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics - Business Wire

Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Business Wire

Sanofi pays Synthekine $40M to join preclinical push against vexing inflammatory target - Fierce Biotech

Sanofi pays Synthekine $40M to join preclinical push against vexing inflammatory target Fierce Biotech

Merck and Synthekine Strike $525 Million Cytokine Therapy Deal - BioSpace

Merck and Synthekine Strike $525 Million Cytokine Therapy Deal BioSpace

Where are they now? Catching up with past Fierce 15 honorees - Fierce Biotech

Where are they now? Catching up with past Fierce 15 honorees Fierce Biotech

Normunity Appoints Debanjan Ray to Board of Directors - citybiz

Normunity Appoints Debanjan Ray to Board of Directors citybiz

AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions - Fierce Biotech

AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions Fierce Biotech

Asher Bio snags $108M series B for immunotherapy programs, push into the clinic - Fierce Biotech

Asher Bio snags $108M series B for immunotherapy programs, push into the clinic Fierce Biotech

AACR 2024: What Cancer Researchers Are Talking About - BioSpace

AACR 2024: What Cancer Researchers Are Talking About BioSpace

Top Synthekine Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant